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Abstract 
The Flow Cytometry: Critical Assessment of Population Identification Methods (FlowCAP) 
challenges were established to compare the performance of computational methods for 
identifying cell populations in multidimensional flow cytometry data. Here we report the results of 
FlowCAP-IV where algorithms from seven different research groups predicted the time to 
progression to AIDS among a cohort of 384 HIV+ subjects, using antigen-stimulated peripheral 
blood mononuclear cell (PBMC) samples analyzed with a 14-color staining panel. Two 
approaches (FlowReMi.1 and flowDensity-flowType-RchyOptimyx) provided statistically 
significant predictive value in the blinded test set. Manual validation of submitted results 
indicated that unbiased analysis of single cell phenotypes could reveal unexpected cell types 
that correlated with outcomes of interest in high dimensional flow cytometry datasets. 
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Introduction 
A wide range of computational tools is required for systematic analysis of high-dimensional and 
high-throughput single cell data in different clinical and experimental settings. Despite recent 
developments in flow cytometry bioinformatics [1], guidance for end users regarding the 
appropriate use of these methods has been scarce. The FlowCAP Consortium has developed a 
series of benchmarks for objective evaluation of computational tools in different settings. 
FlowCAP-I focused on the evaluation of cell population identification algorithms compared to 
manual analysis by human experts for a selection of different cell populations across several 
datasets [2]. While this approach was helpful to demonstrate that algorithms can identify known 
populations, it did not directly address the effectiveness of algorithms that identified cell types 
not previously delineated by the human analysts. To address this limitation the next FlowCAP 
challenges focused on the identification of cellular correlates of an independent biological 
variable (e.g. a clinical outcome). While these challenges demonstrated that computational 
analysis could outperform manual analysis for identification of cell types correlated with external 
factors, they did not establish a benchmark for evaluating the relative performance of data 
analysis pipelines because in one challenge many algorithms were able to achieve perfect 
classification accuracy, whereas in another challenge none of the algorithms (or human expert) 
could successfully identify a cell type that correlated with the clinical outcome. Therefore, a 
more challenging benchmark for evaluation of these algorithms was required to help evaluate 
their relative performance. In this article we report the results of the latest FlowCAP challenge 
that addresses this requirement through the use of a complex dataset to evaluate data analysis 
strategies for identification of correlates of clinical outcome – in this case the time to progression 
to AIDS in HIV positive participants.  
 
Materials and Methods 
We used data from a long-standing natural history study of HIV [3], from which 384 individuals 
were selected, with known HIV seroconversion dates (so that an estimated date of infection 
could be calculated) and long-term clinical follow-up [4].  For each individual, the time to AIDS 
diagnosis (“survival time”) was known, and patients were censored upon initiation of treatment 
or when lost to follow-up. We chose the earliest available cell specimen (<18 months post-
infection (p.i.); mean = 7 months p.i.); our previous analysis showed that the timing of the cell 
specimen had no relationship to survival time.  Cells were stained with two polychromatic flow 
cytometry panels: the first assessed the resting phenotypes of T-cells directly ex vivo [4] (but 
was not used for this study), while the second characterized cytokine and other functional 
responses to HIV, after stimulation with pools of overlapping peptides from HIV-Gag proteins 
(Chattopadhyay et al., under review). Specifically, the latter panel examined the cytokines IFNg, 
IL2, and TNF, along with a costimulatory molecule (CD154) upregulated by CD4+ T-cells upon 
activation and a marker of T-cell degranulation (CD107a).  Cell surface markers that define the 
maturity of the HIV-specific T-cell were examined in this panel as well (CD45RO, CCR7, CD27, 
and CD57) so that the functional responses could be ascribed to cell types well-described in the 
literature (e.g., central memory T-cells, senescent T-cells, etc.). Manual analysis of the dataset 
was performed previously, and showed that no specific characteristics of the anti-HIV T-cell 
response in the selected samples could predict survival time (specifically, the following 
characteristics were tested:  total magnitude of the HIV Gag or Env specific T-cell responses, 
magnitude of individual functional responses, polyfunctionality of the CD4 or CD8 response, and 
differentiation state of the response; these are described in greater detail in a manuscript under 
review (Chattopadhyay, et al)).  It is important to note, however, that the manual data analysis 
examined only cell characteristics that were known to the biologists a priori.  Manual data 
analysis of all possible combinations of markers in the dataset was not feasible.  All selected 
samples from divided into two equal training- and test-sets randomly and uniformly. No 
correlation with the clinical outcome was observed across the two sets (pvalue > 0.22). The 
FlowCAP participants were blinded to the clinical outcomes in the testset, which was used for 
independently verifying the submitted results. 
 
To ensure the feasibility of the study, members of the FlowCAP organizing committee not 
participating in the submission of algorithm results performed an independent analysis [5]. The 
raw Gag-stimulated samples were pre-processed using an optimized logicle transformation [6] 
and 1000 cells per patient were selected randomly. K-means clustering was used to identify 50 
cell types simultaneously in all patients using the pooled cells. For each cluster, the frequency of 
the cells (i.e., the number of cells in the cluster divided by the total number of cells) was used for 
the correlative analysis (Cox-proportional hazards model) on the training set. The median 
expression of each marker for each cell type as well as log-rank p-values for each cluster were 
calculated (Supplemental Figure 1). The most significant clusters included CD3+CD4+ and 
CD3+CD8+ populations that also express a range of other markers (e.g., CD27, CCR7, and IL2) 
and lacked expression of others (e.g., CD57 and TNF). These clusters remained correlated with 
the clinical outcome in the test set, suggesting that successful identification of correlates of 
disease progression in this dataset was possible (Supplemental Figure 2). 
 
Data from unstimulated and Gag-stimulated samples were distributed to all participants. The 
dataset was randomly partitioned into a training set and a test set of equal sizes. The clinical 
information (survival time and censorship status) of the patients in the test set was not provided 
to the participants. Each participant provided a vector of final predictions (extracted from one or 
a combination of several cell types) that was most correlated with the clinical outcome (as 
measured by a lon-rank test on a Cox proportional hazards regression). The complete source 
code as well as the required software packages for independent reproduction of the results was 
also required. The results were evaluated by an independent log-rank test on the blinded test 
set. 
 
Results 
Twenty-four groups requested to participate in FlowCAP-IV and received the data. We received 
9 submissions from 7 groups (Table 1) using combinations of different algorithms including [7]-
[17]. Log-rank test p-values for the submitted result indicated that while several algorithms 
identified cell types strongly correlated with the clinical outcome in the training dataset, only the 
flowDensity-flowType-RchyOptimyx and FloReMi.1 approaches maintained a significant 
correlation (p < 0.05) in the blinded test set. flowDensity is a supervised sequential bivariate 
clustering algorithm that mimics manual gating methods. flowType-RchyOptimyx is an approach 
that uses partitioning of cells into categories (e.g., positive or negative) using 1-D density 
estimate to calculate cut-offs for each marker and  enumerate all cell types in a sample, 
followed by dynamic programing to efficiently construct k-shortest paths to important cell 
populations. FloReMi.1 combines flowType for cell population identification with a random forest 
approach using cell population-based features to build a survival regression model.  One 
version of the three different versions of FloReMi submitted (FloReMi.1) remained significantly 
correlated with the clinical outcome after Bonferroni adjustment for multiple hypothesis testing to 
account for the multiple algorithm submissions submitted (i.e., as the number of submitted 
results increases it is possible that some will have significant correlations in the test dataset due 
to chance alone). 
 
The algorithms used different cell types for the final predictions. For example, FloReMi.1 
identified a CD3+ CD4- CD45RO- CD27- CCR7- population (likely effector CD8+ cells [18], with 
mixed expression of CD57+ and CD57- cells.  Higher frequencies of these cells early in HIV 
disease were correlated with worse prognosis, consistent with previous reports in chronic 
infection[19]. The flowType pipeline identified a CD27- TNF- CD154- population with predictive 
value, but this could not be interpreted further because there was either mixed or negative 
expression of all the other markers studied.  This is not necessarily a limitation of the algorithm; 
it suggests that more markers were needed in the original experiment to positively identify a 
disease correlate.  Still, the result is consistent with that obtained by FloReMi, in that CD27- 
cells were also identified. 
 
Importantly, several algorithms identified populations within the CD14/VIVID+ channel, originally 
designed to exclude dead cells and monocytes. Cluster #3 of our independent analysis 
(Supplemental Figure 1) further describes this population, which includes CD3+ CD4- 
CD14/VIVID+ CD57- cells. This cluster was correlated with outcome both in the training and test 
sets. To validate this population, we constructed a gating strategy for this cell type 
(Supplemental Figure 3) and applied it to the unstimulated set of samples. The correlation with 
the clinical outcome was preserved (Supplemental Figure 4), arguing against the possibility of 
experimental artifact, since the identified population appeared significant in all samples 
(stimulated and unstimulated).  Stated differently, since the population lacked cytokine-
expressing cells, we expected to observe it (and find the same clinical correlations) in the 
unstimulated samples.  Finally, we confirmed these results in a different dataset from the same 
cohort[10], using manual gates to identify the CD3+ CD4- CD14/VIVID+ CD57- cells. The 
boundaries of the gates were manually adjusted using FlowJo (Treestar Inc, Ashland, OR) to 
account for technical variations across the two datasets. The frequency of the manually 
identified cell type remained correlated with the clinical outcome (Supplemental Figure 5), 
confirming robustness of the results in this dataset. 
 
We performed additional experiments to better define these cells.  Based on their phenotype, 
we surmised that the correlation arose from dead cells or live monocytes.  Notably, although the 
cells appeared CD3+, this was likely a consequence of well-known experimental artifacts: non-
specific antibody binding by dead cells [20] and/or monocyte binding of our mouse anti-human 
IgG1 CD3 antibody via FCgRIIA (CD32A, [21]).  To disentangle the staining patterns of the 
viability marker between dead cells and monocytes, we stained cells with VIVID and then 
measured CD14 expression using a different fluorochrome.  Live, CD14+ monocytes bound 
intermediate levels of VIVID compared to live lymphocytes and dead monocytes (Supplemental 
Figure 6); a likely result of the increased size and protein content of live monocytes compared to 
lymphocytes[20]. This suggested that the correlation found in the dataset represented live 
monocytes, not dead cells (further confirmed by a separate experiment, where the correlate 
population expressed other markers of monocytes, CD16 and CD11c).  This was confirmed by 
testing viability data from the original dataset, obtained using microscopic examination of 
ethidium bromide/acridine orange stained cells (EB/AO) at the time of thaw.  There was no 
relationship between the frequency of dead cells, or the number of cells recovered from the vial 
as measured by a hemocytometer, and survival times (Supplemental Figure 7).  This strongly 
suggests that monocytes accounted for the correlation between CD14+/VIVID+ cells in early 
infection and survival time, consistent with previous data [22]-[25]. This analysis demonstrates 
how careful analysis of biology, experimental artifacts, and computational results can provide an 
unbiased analysis of all available cells, revealing unexpected cell types that correlate with 
clinical outcomes. 
 
Discussion 
As high throughput and high dimensional flow and mass cytometry datasets become 
increasingly common, there is a critical need for automated data analysis approaches.  As 
demonstrated by our HIV natural history studies, correlates of survival often lie within complex 
populations of cells not typically queried by directed, manual data analysis. Comprehensive 
analysis of a dataset, in which cells expressing all possible combinations of markers are 
examined, is unfeasible with classical, manual data analysis alone.  Fortunately, there are a 
wide variety of approaches to automated data analysis. However, there have been few carefully 
controlled comparative studies that have assessed their performance.  FlowCAP provides a 
forum for such comparison. 
 
FlowCAP-IV was designed to address the limitations in some of the past challenges by using a 
dataset containing complex correlates of an externally defined variable (time to AIDS 
progression/diagnosis). Participants were provided a training set and their submitted results 
(survival status) on a blinded and independent test set.  There were a number of reasons this 
dataset was selected for a FlowCAP challenge. It contained well-defined clinical data, providing 
a standardized and meaningful outcome variable. The data was also robustly collected using 
stringent quality control approaches, with previous studies performed in the same cohort of 
individuals. A variety of parameters were examined in this study, including multiple markers of 
T-cell maturity and function, providing a complex test.  Our previous analysis also suggested 
that correlates of survival were contained within complex cell populations, and thus would be 
challenging to identify.  Finally, the size of the dataset was consistent with the types of studies 
increasingly performed today, for which better data analysis solutions are needed.  
 
A key product of our work with automated data analysis is the recognition that correlates of 
biologically important outcomes can lie in cell types that are not well described in the literature.  
In fact, the reliance on classically defined cell types for manual data analysis is problematic in 
high-dimensional experiments, as the definition of a particular cell type might differ by 
investigator or paper. For example, a central memory T-cell in one study may be CD45RA- 
CCR7+, while in another study the cell is defined as CD45RA- CD27+.  When all of these 
markers are measured together in a sample, it becomes difficult to decide which combination of 
markers should define the cell type of interest and only a few cell populations are assessed due 
to the burden of manual analysis.  In this regard, automated unbiased approaches that consider 
expression of all markers are vastly preferable since no potentially important cell populations 
are missed; this is a feature of all the automated approaches tested in this challenge. Notably, 
we show here that pre-gating data (to remove dead cells or monocytes, for example) can cause 
similar problems, as the excluded cell types may include correlates.  However, this 
consideration is balanced by the problem of interpreting biology from the potentially artifactual 
staining patterns on the excluded cells. 
 
The methods included in this study can be broken into several components: 1) Preprocessing 
(e.g., transformation [26] and normalization [27]); 2) feature extraction (e.g., clustering [28], 
probability binning [29], combinatorial gating [7], [10], and cluster matching [30], [31]);  3) 
supervised analysis (e.g., single-variate [32]-[34] and multi-variate models [35]); 4) 
characterization [8], [36] and visualization [16], [37], [38]. Not only do these components vary in 
their individual performance across different biological applications, their interactions with each 
other in a large data analysis pipeline also further complicates the choice of appropriate 
methods [39]  The establishment of objective benchmarks like the one reported here enables 
further analysis in which different components are examined subject to a wide range of technical 
and biological variations to identify the combination with optimal performance.  It is also possible 
that the optimal combination may differ by data type or study design. FlowCAP provides a 
platform for future evaluation of these possibilities. 
 
Availability 
Raw data, clinical meta-data, and the submissions by the participants including software are 
publically available at http://flowrepository.org[40], under repository ID FR-FCM-ZZ99 and 
(Note: this code will be activated only upon publication. Reviewer access is available through: 
http://flowrepository.org/id/RvFrXVcrR4m0jEcsoPpnEdziUfaVUtGYdXZw4bEqvlnGfRX9aSYNSlt
B4bdTG4DH).  
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 Table 1: A summary of all submitted results. 
 
 
Name Approach Availability Reference 
BorFlowFP 
Exhaustive all-relevant feature selection with the 
Boruta method over the flow cytometry 
fingerprints data followed by modeling with 
Survival Random Forest algorithm. 
Boruta and FlowFP are 
free, open-source R 
packages available from 
CRAN and BioConductor, 
respectively. 
 
 
[15] 
FloReMi.1 
Partitioning of cells (e.g., into positive or 
negative) to identify cell populations, followed by 
feature extraction of both cell population size 
and MFI values. Features with minimal 
redundancy were selected as input for a random 
survival forest for survival time prediction. 
R Code to reproduce our 
results is available at 
www.github.com/SofieVG
/FloReMi and in 
Supplementary data from 
FlowRepository.org 
[12] 
FloReMi.2 As FloReMi.1, but using a Cox-proportional 
hazards model for survival time prediction R Code to 
reproduceresults is 
available at 
www.github.com/SofieVG
/FloReMi and in 
supplementary data from 
FlowRepository.org 
[12] 
FloReMi.3 As FloReMi.1, but using an additive hazards 
model for survival time prediction R Code to reproduce 
results is available at 
www.github.com/SofieVG
/FloReMi and in 
supplementary data from 
FlowRepository.org 
[12] 
flowDensity/flowType/
RchyOptimyx 
Density-based getting and partitioning of cells 
(e.g., into positive or negative) followed by 
dynamic programing to ID k-shortest paths to 
important cell populations 
Free, open-source R 
packages available from 
BioConductor 
[10,7,8,9] 
GANN Identifying profiles of individual bin channels of 
fluorescence for the different cell markers which 
can be used for distinguishing different groups / 
categories 
C++ written program, 
available by contacting 
the author and in 
supplementary data from 
FlowRepository.org 
[11,13,14] 
RTOMT 
Partitioning of cells (e.g., into positive or 
negative). Combining clinical diagnosis and 
survival time into a single target 
vector.  Regression tree. 
Free, open-source code, 
Matlab available in 
supplementary data from 
FlowRepository.org 
NA 
SPADE.SNR 
SPADE was used to derive cell clusters in high-
dimensional space. Important clusters were 
selected by a signal-to-noise ratio based on cell 
frequency of subjects who showed disease 
progression. 
Freely available 
implementation in Matlab 16 
EMMIXflow 
Clustering using expectation maximization fitting 
of skew-t mixture models was used for feature 
extraction. A random survival forest was used 
for building the predictive model. 
R source code available 
in supplementary data 
from FlowRepository.org 
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(A) (B) 
Figure 1: The log-rank test p-values of the submissions on (A) the training-set and (B) the test-set. 
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Supplemental Information 
 
 
Supplemental Figure 1: Independent analysis of the FlowCAP-IV dataset. 50 cell-types were identified using 
the K-means clustering algorithm. The heatmap demonstrates the median expression for each marker 
(column) in the cells of each cluster (rows). The p-values of the log-rank tests on the training set are 
visualized using bar plots on the right. 
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Supplemental Figure 2: Kaplan-Meier curves for the best cell type (#3) from the independent K-means 
analysis on the training and test dataset. The patients were divided into two groups using the best possible 
threshold by testing all percentiles. 
 
Supplemental Figure 3: A manual gating strategy for identification of the cluster most correlated with the 
clinical outcome from the independent K-means analysis (cluster  #3, Figure 1). The polygons (starting from 
top-left moving to right) can recapitulate the high-dimensional cell type with the purity, recall, and F-measure 
(average of precision and recall) visualized on the last panel (bottom-right). The red dots are the cells of 
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interest, the black dots are all other cells, and the gray dots are the dots excluded in the previous gating 
step. 
 
Supplemental Figure 4: Kaplan-Meier curves for the manual gating strategy applied to the unstimulated 
samples to confirm robustness of the results to Gag stimulation. The patients were divided into two groups 
using the best possible threshold by testing all cell frequency divisions. 
 
 
0 5 10 15
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Years
Ev
en
t f
re
e 
su
rv
iva
l
Cell frequency
> 0.100566
< 0.100566
p−value = 2e−05
 
Supplemental Figure 5: Kaplan-Meier curves for the manual gating strategy applied to a confirmatory dataset 
from the same cohort. The patients were divided into two groups using the best possible threshold by 
testing all cell frequency divisions. 
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Supplemental Figure 6: The correlate of protection found in the FlowCAP-IV dataset amongst VIVID/CD14+ 
cells likely represents a population of live CD14+ cells, not dead cells.  When cells are stained with VIVID and 
CD14 using separate fluorochromes, it becomes clear that CD14+ cells bind more VIVID than CD14- cells 
(first panel), as a consequence of increased size and protein content.  Thus, the distribution of VIVID staining 
for live monocytes overlaps with dead CD14- lymphocytes (second panel), and the measurement of these 
two markers in the same channel in the original dataset complicates biological interpretation of the data.  
The high expression of CD16 and CD11c by these cells (third panel) is consistent with their 
monocyte/myeloid classification. In the second panel the blue curve shows live/dead staining among 
lymphocytes, with the left peak representing live cells, and the right peak representing dead cells.  The red 
curve shows live/dead staining in monocytes.  This curve is right-shifted, such that live monocytes overlap 
with dead lymphocytes.  Dead monocytes are found in the brightest peak of the red curve. 
 
  
(A) (B) 
Supplemental Figure 7: Kaplan-Meier curves based on the frequency of dead cells (left) and the proportion of 
cells recovered from each vial (right). The patients were divided into two groups using the best possible 
threshold by testing all frequency divisions. 
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